Novo Nordisk Launches Study to Determine Optimal Dosage of Wegovy Pill for Weight Loss, ETPharma
London: Danish drugmaker Novo Nordisk is testing lower doses of its Wegovy pill in a new late-stage study…
Novo Nordisk receives European Commission approval of
First GLP-1 pill approved in the European Union for the treatment of obesity and overweightOnly Wegovy® pill demonstrates…
Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes
Approval is based on results from the OASIS 4 trial, which investigated semaglutide tablets 25 mg in adults…
Novo Nordisk Stock Up as UK Wegovy Pill Nod Eclipses Security Breach
Novo Nordisk NVO shares gained 2.7% on Thursday as investors focused on a major regulatory milestone for its obesity…
Novo Nordisk’s Wegovy pill approved in the UK
!- – Start GPT Tag – ->
<!- – End GPT Tag – ->
…
Novo Nordisk reports 3 million Wegovy pill prescriptions
Novo Nordisk (NYSE:NVO) announced that prescriptions for the oral version of Wegovy have exceeded 3 million since the…
Novo Nordisk’s Wegovy pill wins key EU backing | NVO SEC Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT…
Novo Nordisk Highlights New Wegovy Pill Data
Novo Nordisk A/S (NYSE:NVO) presented new analyses from its phase 3 OASIS 4 clinical trial at the European…
Novo Nordisk Q1 2026 Earnings: Revenue, Profit Beat; Full-Year Forecast Narrowed | Reuters – News and Statistics
May 7, 2026 Novo Nordisk, the manufacturer of the weight-loss drug Wegovy, reported first-quarter revenue and adjusted operating…
Novo sees comeback as weight-loss pill boom revives investor confidence – Firstpost
Novo Nordisk shares surged after strong demand for its new weight-loss pill helped the Danish drugmaker beat quarterly…
Novo Nordisk’s adjusted operating profit reached DKK 32,858
Bagsværd, Denmark, 6 May 2026 – Financial report for the period 1 January 2026 to 31 March 2026…
Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock
BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an…